Colloidal carriers: A promising way to treat central nervous system diseases

Journal of Nanoneuroscience

Volumn 1, Issue 1, 2009, Pages 17-34

  Andrieux, Karine ^a   Garcia Garcia, Elizabeth ^b   Kim, Hyun Ryoung ^c   Couvreur, Patrick ^a,d,e,f  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c Samsung Advanced Institute of Technology (SAIT)   (South Korea)

^d UNIV PARIS SUD   (France)

^e Academy of Pharmacy   (France)

^f Royal Academy of Medicine   (Belgium)

Author keywords

Blood brain barrier; Brain pathologies; Colloidal carriers; Drug delivery

Indexed keywords

CARMUSTINE; CHOLINESTERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG CARRIER; FLUOROURACIL; LEVODOPA; LIPOSOME; MACROGOL; MONOAMINE OXIDASE B INHIBITOR; NANOCARRIER; NANOPARTICLE;

ALZHEIMER DISEASE; BIODEGRADABILITY; BLOOD BRAIN BARRIER; BRAIN DISEASE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COLLOID; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG TRANSPORT; GLIOMA; HUMAN; MICELLE; MULTIPLE SCLEROSIS; NANOENCAPSULATION; NONHUMAN; PARKINSON DISEASE; PHYSICAL CHEMISTRY; REVIEW; SUSTAINED DRUG RELEASE;

EID: 76149099893     PISSN: 19390637     EISSN: 19390653     Source Type: Journal    
DOI: 10.1166/jns.2009.003     Document Type: Review

References (175)

1. Abbott NJ, Romero IA (1996) Transporting therapeutics across the bloodbrain barrier. Mol Med Today 2:106.
2. Adams ML, Lavasanifar A, Kwon GS (2003) Amphiphilic block copolymers for drug delivery. J Pharm Sci 92:1343.
3. Aktaş Y, Andrieux K, Alonso MJ, Calvo P, Gürsoy RN, Couvreur P, Capan Y (2005a) Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 298:378.
4. Aktaş Y, Yemisci M, Andrieux K, Gürsoy RN, Alonso MJ, Fernandez-Megia E, Novoa-Carballal R, Quiñoá E, Riguera R, Sargon MF, Celik HH, Demir AS, Hincal AA, Dalkara T, Capan Y, Couvreur P (2005b) Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 16:1503.
5. Alakhov V, Klinski E, Li S, Pietrzynski G, Venne A, Batrakova E, Bronitch TK, Kabanov A (1999) Block copolymer-based formulation of doxorubicin.From cell screen to clinical trial. Colloids Surf B Biointerfaces 16:113.
6. Allen C, Maysinger D, Eisenberg A (1999) Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces 16:3.
7. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:325.
8. Andresen TL, Jensen SS, Jorgensen K (2005) Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44:68.
9. Artzner F, Zantl R, Radler JO (2000) Lipid-DNA and lipidpolyelectrolyte mesophases: structure and exchange kinetics. Cell Mol Biol 46:967.
10. Badger J, Stins M, Kim KS (1999) Citrobacter Freundii invade and replicates in human brain microvascular endothelial cells. Infect Immun 67:4208.
11. Bagger MA, Bechgaard E (2004) The potential of nasal application for delivery to the central brain a microdialysis study of fluorescenin in rats. Eur J Pharm Sci 21:235.
12. Banks WA, Freed EO, Wolf KM, Robinson SM, Franko M, Kumar VB (2001) Transport of human immunodeficiency virus type 1 pseudoviruses across the blood-brain barrier: role of envelope proteins and adsortive endocytosis. J Virol 75:4681.
13. Barratt G, Couarraze G, Couvreur P, Dubernet C, Fattal E, Gref R, Labarre D, Legrand P, Ponchel G, Vauthier C (2001) Polymeric micro-and nanoparticles as drug carriers.Polymeric Biomaterials (Dumitriu S, ed), pp 753-781. Marcel Dekker, New York.
14. Bartus RT, Elliott PJ, Dean RL, Hayward NJ, Nagle TL, Huff MR, Snodgrass PA, Blunt DG (1996) Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7.Exp Neurol 142:14.
15. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV (2001a) Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 299:483.
16. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF (2001b) Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 296:551.
17. Benoit JP, Faisant N, Venier-Julienne MC, Menei P (2000) Development of microspheres for neurological disorders: from basics to clinical applications, J Control Release 65:285.
18. Bickel U, Kang Y-S, Huwyler J (2001) Brain-specific drug targeting strategies.Drug Targeting (Molema G, Meijer D, eds), pp 23-52. Wiley-VCH, Germany.
19. Black KL, Ningaraj NS (2004) Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor. Cancer Control 11:165.
20. Boado RJ (2007) Blood-brain barrier transport of non-viral gene and RNAi therapeutics. Pharm Res 24:1772.
21. Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA (2004) Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 78:6567.
22. Bodor N, Buchwald P (1999) Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev 36:229.
23. Bolton SJ, Anthony DC, Perry VH (1998) Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 86:1245.
24. Borchard G, Audus KL, Shi F, Kreuter J (1994) Uptake of surfactantcoated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm 110:29.
25. Borlongan CV, Emerich DF (2003) Facilitation of drug entry into the CNS via transient permeation of blood-brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull 60:297.
26. Brigger I, Dubernet C, Couvreur P (2002a) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631.
27. Brigger I, Morizet J, Aubert G, Chacun H, Terrier-Lacombe MJ, Couvreur P, Vassal G (2002b) Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting. J Pharmacol Exp Ther 303:928.
28. Brigger I, Morizet J, Laudani L, Aubert G, Appel M, Velasco V, Terrier-Lacombe MJ, Desmaële D, d'Angelo J, Couvreur P, Vassal G (2004) Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release 100:29.
29. Calvo P, Gouritin B, Villarroya H, Eclancher F, Giannavola C, Klein C, Andreux JP, Couvreur P (2002) Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur J Neurosci 15:1317.
30. Calvo P, Gouritin B, Brigger I, Lasmezas C, Deslys J, Williams A, Andreux JP, Dormont D, Couvreur P (2001a) PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases. J Neurosci Methods 111:151.
31. Calvo P, Gouritin B, Chacun H, Desmaele D, D'Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P (2001b) Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18:1157.
32. Chamberlain MC, Kormanik PA, Barba D (1997) Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 87:694.
33. Chatterjee S, Banerjee DK (2002) Preparation, isolation, and characterization of liposomes containing natural and synthetic lipids. Methods Mol Biol 199:3.
34. Chauhan NB (2002) Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain. Antisense Nucleic Acid Drug Dev 12:353.
35. Chiu SJ, Liu S, Perrotti D, Marcucci G, Lee RJ (2006) Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112:199.
36. Chow HH, Anavy N, Villalobos A (2001) Direct nose-brain transport of benzoylecgonine following intranasal administration in rats. J Pharm Sci 90:1729.
37. Cloughesy T, Black K, Gobin Y, Farahani K, Nelson G, Villablanca P, Kabbinaver F, Vinuela F, Wortel C (1999) Intra-arterial Cereport (RMP-7) and carboplatin: a dose escalation study for recurrrent malignant gliomas. Neurosur gery 44:270.
38. da Cruz MT, Simoes S, de Lima MC (2004) Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. Exp Neurol 187:65.
39. Dahlin M, Bergman U, Jansson B, Bjork E, Brittebo E (2000) Transfer of dopamine in the olfactory pathway following nasal administration in mice. Pharm Res 17:737.
40. Dai C, Holland EC (2001) Glioma models. Biochim Biophys Acta 1551:M19-M27.
41. Davis SS (1997) Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 15:217.
42. Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51:10.
43. Fattal E, Vauthier C (2002) Nanoparticles as drug delivery systems. Encyclopedia of Pharmaceutical Technology, pp 1864-1882. Marcel Dekker, New York.
44. Fiala M, Looney DJ, Stins M, Way DD, Zhang L, Gan X, Chiappelli F, Schweitzer ES, Shapshak P, Weinand M, Graves MC, Witte M, Kim KS (1997) TNF-alpha opens a paracellular route for HIV-1 invasion across the blood-brain barrier. Mol Med 3:553.
45. Fiorillo A, Maggi G, Greco N, Migliorati R, D'Amico A, De Caro MD, Sabbatino MS, Buffardi F (2004) Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors. J Neurooncol 66:179.
46. Fishman JB, Rubin JB, Handrahan JV, Connor JR, Fine RE (1987) Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J Neurosci Res 18:299.
47. Fournier E, Passirani C, Montero-Menei C, Colin N, Breton P, Sagodira S, Menei P, Benoit JP (2003a) Therapeutic effectiveness of novel 5-fluorouracil-loaded poly(methylidene malonate 2.1.2)-based microspheres on F98 glioma-bearing rats. Cancer 97:2822.
48. Fournier E, Passirani C, Vonarbourg A, Lemaire L, Colin N, Sagodira S, Menei P, Benoit JP (2003b) Therapeutic efficacy study of novel 5-FU-loaded PMM 2.1.2-based microspheres on C6 glioma. Int J Pharm 268:31.
49. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J (2000) Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm 49:103.
50. Gabizon AA (1992) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52:891.
51. Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, Rong Z, Chen H, Jiang X (2007) Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 121:156.
52. Garcia-Garcia E, Gil S, Andrieux K, Desmaële D, Nicolas V, Taran F, Georgin D, Andreux JP, Roux F, Couvreur P (2005a) A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cell Mol Life Sci 62:1400.
53. Garcia-Garcia E, Andrieux K, Gil S, Kim HR, Le Doan T, Desmaële D, d'Angelo J, Taran F, Georgin D, Couvreur P (2005b) A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm 298:310.
54. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J (2002) Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett 126:131.
55. Gref R, Couvreur P, Barratt G, Mysiakine E (2003) Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 24:4529.
56. Grondin R, Zhang Z, Ai Y, Gash DM, Gerhardt GA (2003) Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog Drug Res 61:101.
57. Guerin C, Olivi A, Weingart JD, Lawson HC, Brem H (2004) Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. In vest New Drugs 22:27.
58. Gupta B, Levchenko TS, Torchilin VP (2007) TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res 16:351.
59. Han LM, Guo J, Zhang LJ, Wang QS, Fang XL (2006) Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 27:747.
60. Hashizume K, Black KL (2002) Increased endothelial vesicular transport correlates with increased blood-tumor barrier permeability induced by bradykinin and leukotriene C4. J Neuropath Exp Neurol 61:725.
61. Hau P, Fabel K, Baumgart U, Rummele P, Grauer O, Bock A, Dietmaier C, Dietmaier W, Dietrich J, Dudel C, Hubner F, Jauch T, Drechsel E, Kleiter I, Wismeth C, Zellner A, Brawanski A, Steinbrecher A, Marienhagen J, Bogdahn U (2004) Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100:1199.
62. Huang SH, Jong AY (2001) Cellular mechanisms of microbial proteins contributing to invasion of the blood-brain barrier. MicroRe view Cell Microbiol 3:277.
63. Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) Clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50:140.
64. Huwyler J, Wu D, Pardridge WM (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164.
65. Illum L (2000) Transport od drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1.
66. Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 53:3.
67. Jacob JN, Hesse GW, Shashoua VE (1990) Synthesis, brain uptake, and pharmacological properties of a glyceryl lipid containing GABA and the GABA-T inhibitor gamma-vinyl-GABA. J Med Chem 33:733.
68. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY (1984) Transferrin receptor on endothelium of brain capillaries. Nature 312:162.
69. Jeon SI, Lee JH, Andrade JD, De Gennes PG (1991) Protein-surface interactions in the presence of polyethylene oxide: I. simplified theory. J Colloid Interface Sci 142:149.
70. Jollivet C, Aubert-Pouessel A, Clavreul A, Venier-Julienne MC, Remy S, Montero-Menei CN, Benoit JP, Menei P (2004) Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 25:933.
71. Jones M, Leroux J (1999) Polymeric micelles-a new generation of colloidal drug carriers.Eur J Pharm Biopharm 48:101. Kabanov A (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trial. Colloids Surf B Biointerfaces 16:113.
72. Kabanov AV, Batrakova EV (2004) New technologies for drug delivery across the blood-brain barrier. Curr Pharm Des 10:1355.
73. Kabanov AV, Batrakova EV, Melik-Nubarov NS, Fedoseev NA, Dorodnich TY, Alakhov VY, Chekhonin VP, Nazarova IR, Kabanov VA (1992) New clases of drug carries: micelles of poly(oxyethylene)-poly(oxypropylene) block copolymers as microcontainers for drug targeting form blood in brain. J Control Release 22:141.
74. Kim HR, Andrieux K, Delomenie C, Chacun H, Appel M, Desmaële D, Taran F, Georgin D, Couvreur P, Taverna M (2007a) Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis 28:2252.
75. Kim HR, Gil S, Andrieux K, Nicolas V, Appel M, Chacun H, Desmaële D, Taran F, Georgin D, Couvreur P (2007b) Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cell Mol Life Sci 64:356.
76. Kim HR, Andrieux K, Gil S, Taverna M, Chacun H, Desmaële D, Taran F, Georgin D, Couvreur P (2007c) Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8:793.
77. Kono K, Iwamoto M, Nishikawa R, Yanagie H, Takagishi T (2000) Design of fusogenic liposomes using a poly(ethylene glycol) derivative having amino groups. J Control Release 68:225.
78. Koukourakis MI, Koukouraki S, Giatromanolaki A, Kakolyris S, Georgoulias V, Velidaki A, Archimandritis S, Karkavitsas NN (2000) High intratumoral accumulation of Stealth® liposomal doxorubicin in sarcomas-rationale for combination with radiotherapy. Acta Oncol 39:207.
79. Kreuter J (1992) Nanoparticles-preparation and applications.Microcapsules and Nanoparticles in Medicine and Pharmacy (Donbrow M, ed), pp 123-148. CRC Press, Boca Raton, London.
80. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA (1995) Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674:171.
81. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R (2002) Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 10:317.
82. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20:409.
83. Kshirsagar NA, Pandya SK, Kirodian GB, Sanath S (2005) Liposomal drug delivery system from laboratory to clinic. J Postgrad Med 51:S5.
84. Lambert DM (2000) Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 11:S15.
85. Li H, Qian ZM (2002) Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev 22:225.
86. Li Y, Ogris M, Wagner E, Pelisek J, Rüffer M (2003) Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation. Int J Pharm 259:93.
87. Lichtenberg D, Barenholz Y (1988) Liposomes: preparation, characterization, and preservation. Methods Biochem Anal 33:337.
88. Lindner MD, Emerich DF (1998) Therapeutic potential of a polymerencapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease. Cell Transplant 7:165.
89. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000) Analysis of human immnodeficiency virus type 1 gp 160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurolvirol 6:S70.
90. Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M (2002) Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76:6689.
91. Lo EH, Singhal AB, Torchilin VP, Abbott NJ (2001) Drug delivery to damaged brain. Brain Res Brain Res Rev 38:140.
92. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271.
93. Manjunath K, Reddy JS, Venkateswarlu V (2005) Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 27:127.
94. Martin TA, Jiang WG (2001) Tight junction and their role in cancer metastasis. Histol Histopathol 16:1183.
95. Maruyama K, Ishida O, Kasaoka S, Takizawa T, Utoguchi N, Shinohara A, Chiba M, Kobayashi H, Eriguchi M, Yanagie H (2004) Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release 98:195.
96. Matsuo H, Okamura T, Chen J, Takanaga H, Ohtani H, Kaneda Y, Naito M, Tsuruo T, Sawada Y (2000) Efficient introduction of macromolecules and oligonucleotides into brain capillary endothelial cells using HVJ-liposomes. J Drug Target 8:207.
97. McIntosch TK, Saatman RE, Raghupathi R, Graham DI, Smith DH, Lee VM, Trojanowski JQ (1998) Molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol 24:251.
98. Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D, Delhaye M, Benoit JP (2004) Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 100:405.
99. Miller G (2002) Breaking down barriers. Science 297:1116.
100. Misra A, Ganesh S, Shahiwala A, Shah SP (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6:252.
101. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, Khatri K, Vyas SP (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14:45.
102. Mizuno M, Ryuke Y, Yoshida J (2002) Cationic liposomes conjugation to recombinant adenoviral vectors containing herpes simplex virus thymidine kinase gene followed by ganciclovir treatment reduces viral antigenicity and maintains antitumor activity in mouse experimental glioma models. Cancer Gene Ther 9:825.
103. Moghimi SM, Hunter AC, Murray JC (2001) Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev 53:283.
104. Mozafari MR (2005) Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 10:711.
105. Neuwelt EA (2004) Mechanisms of disease: the blood-brain barrier. Neurosurgery 54:131.
106. Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, Barnett PA (1979) Osmotic blood-brain barrier disruption.Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 64:684.
107. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307.
108. Norimoto N, Pollack IF, Storkus WJ, Wakabayashi T, Yoshida J, Okada H (2003) Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-b gene vector and dendritic cells. Cancer Gene Ther 10:549.
109. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343:938.
110. Ogris M, Steinlein P, Carotta S, Brunner S, Wagner E (2001) DNA/polyethylenimine transfection particles: influence of ligands, polymer size, and PEGylation on internalization and gene expression. AAPS PharmSci 3:E21.
111. Olivier JC (2005) Drug transport to brain with targeted nanoparticles. NeuroRx 2:108.
112. Olivier JC, Huertas R, Lee HJ, Calon F, Pardridge WM (2002) Synthesis of pegylated immunonanoparticles. Pharm Res 19:1137.
113. Olivier JC, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W (1999) Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res 16:1836.
114. Owens T, Sriram S (1995) The immunology of multiple sclerosis and its animal model, experimental allergic encephalomyelitis. Multiple Sclerosis 13:51.
115. Owens DE, 3rd, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93.
116. Papadopoulos MC, Saadount S, Davies DC, Bell BA (2001a) Emerging molecular mechanisms of brain tumor oedema. Br J Neurosurg 15:101.
117. Papadopoulos MC, Saadount S, Woodrow CJ, Davies DC, Costa-Martins P, Moss RF, Krishna S, Bell BA (2001b) Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol 27:384.
118. Pardridge WM (2002) Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol 513:397.
119. Pardridge WM, Eisenberg J, Yang J (1987) Human blood-brain barrier transferrin receptor. Metabolism 36:892.
120. Peracchia MT, Vauthier C, Desmaele D, Gulik A, Dedieu JC, Demoy M, d'Angelo J, Couvreur P (1998) Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm Res 15:550.
121. Peracchia MT, Fattal E, Desmaele D, Besnard M, Noel JP, Gomis JM, Appel M, d'Angelo J, Couvreur P (1999a) Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J Control Release 60:121.
122. Peracchia MT, Harnisch S, Pinto-Alphandary H, Gulik A, Dedieu JC, Desmaele D, d'Angelo J, Muller RH, Couvreur P (1999b) Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials 20:1269.
123. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, Fiala M, Way D, Kim KS, Witte MH, Weinand M, Carhart L, Gendelman HE (1999) Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 155:1599.
124. Petty MA, Lo EH (2002) Junctional complexes of the blood-brain barrier: permeability changes in neuroinflammation. Prog Neurobiol 68:311.
125. Qian ZM, Li H, Sun H, Ho K (2002) Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 54:561.
126. Qin J, Chen D, Hu H, Qiao M, Zhao X, Chen B (2007) Body distributioin of RGD-mediated liposome in brain-targeting drug delivery. Y akugaku Zasshi 127:1497.
127. Ring A, Weiser JN, Toumanen EI (1998) Pneumococcal trafficking across the blood-brain barrier: molecular analysis of a novel bidirectional pathway. J Clin Invest 102:347.
128. Roessler BJ, Davidson BL (1994) Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes. Neurosci Lett 167:5.
129. Saba TM (1970) Physiology and physiopathology of the reticuloendothelial system. Arch Intern Med 126:1031.
130. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, Kirpotin DB, Park JW, Berger MS, Bankiewicz KS (2004) Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res 64:2572.
131. Salem AK, Cannizzaro SM, Davies MC, Tendler SJ, Roberts CJ, Williams PM, Shakesheff KM (2001) Synthesis and characterisation of a degradable poly(lactic acid)-poly(ethylene glycol) copolymer with biotinylated end groups. Biomacromolecules 2:575.
132. Samad A, Sultana Y, Aqil M (2007) Liposomal drug delivery systems: an update review. Curr Drug Deliv 4:297.
133. Sarti P, Ginobbi P, D'Agostino I, Arancia G, Lendaro E, Molinari A, Ippoliti R, Citro G (1996) Liposomal targeting of leukaemia HL60 cells induced by transferrin-receptor endocytosis.Biotechnol. Appl Biochem 24:269.
134. Schlageter KE, Molnar P, Lapin GD, Groothuis DR (1999) Microvessel organization and strcuture in experimental brain tumors: microvessel population with distinctive structural and functional properties. Microvasc Res 58:312.
135. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R (2003) Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain 126:1895.
136. Schroeder U, Sommerfeld P, Sabel BA (1998) Efficacy of oral dalarginloaded nanoparticle delivery across the blood-brain barrier. Peptides 19:777.
137. Seligman PA (1983) Structure and function of the transferrin receptor. Prog Hematol 13:131.
138. Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates.Crit Rev Ther Drug Carrier Syst 9:135. Shangguan T, Pak CC, Ali S, Janoff AS, Meers P (1998) Cationdependent fusogenicity of an N-acyl phosphatidylethanolamine. Biochim Biophys Acta 68:225.
139. Shashoua VE, Hesse GW (1996) N-docosahexaenoyl, 3 hydroxytyramine: a dopaminergic compound that penetrates the blood-brain barrier and suppresses appetite. Life Sci 58:1347.
140. Shi N, Boado RJ, Pardridge WM (2001) Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res 18:1091.
141. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83:1029.
142. Soni S, Babbar AK, Sharma RK, Maitra A (2006) Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J Drug Target 14:87.
143. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1.
144. Staber PB, Linkesch W, Zauner D, Beham-Schmid C, Guelly C, Schauer S, Sill H, Hoefler G (2004) Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia. Oncogene 23:894.
145. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109:759.
146. Szoka F, Jr, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467.
147. Terasaki T, Hosoya K (1999) The blood-brain barrier efflux transporters as a detoxifying system for the brain. Adv Drug Deliv Rev 36:195.
148. Tessmar JK, Mikos AG, Gopferich A (2002) Amine-reactive biodegradable diblock copolymers. Biomacromolecules 3:194.
149. Torchilin VP (1994) Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods 4:244.
150. Tsao N, Chang WW, Liu CC, Lei HY (2002) Development of hematogenous pneumococcal meningitis in adult mice: the role of TNF-[alpha]. FEMS Immunol Med Microbiol 32:133.
151. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatinincorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93:678.
152. Ulrich AS (2002) Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep 22:129.
153. Vajkoczy P, Menger MD (2001) Vascular microenvironment in gliomas. J NeuroOncol 50:99.
154. Vinogradov SV (2007) Polymeric nanogel formulations of nucleoside analogs. Expert Opin Drug Deliv 4:5.
155. Vinogradov SV, Batrakova EV, Kabanov AV (1999) Poly(ethylene glycol)-polyethyleneimine Nanogel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf B Biointerfaces 16:291.
156. Vinogradov SV, Bronich TK, Kabanov AV (2002) Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells.Adv Drug Deliv Rev 54:135.
157. Vinogradov SV, Batrakova EV, Kabanov AV (2004) Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem 15:50.
158. Visser CC, Stevanovic S, Voorwinden LH, van Bloois L, Gaillard PJ, Danhof M, Crommelin DJ, de Boer AG (2005) Targeting liposomes with protein drugs to the blood-brain barrier in vitro.Eur J Pharm Sci 25:299.
159. Wang Y, Kim KS (2002) Role of OmpA and IbeB in Escherichia coli K1 invasion of brain microvascular endothelial cells in vitro and in vivo. Pediatr Res 51:559.
160. Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987.
161. Wang Y, Aun R, Tse FL (1998) Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat. Biopharm Drug Dispos 19:571.
162. Wei G, Wang D, Lu H, Parmentier S, Wang Q, Panter SS, Frey WH, 2nd, Ying W (2007) Intranasal administration of a PARG inhibitor profoundly decreases ischemic brain injury. Front Biosci 12:4986.
163. Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257.
164. Witt KA, Huber JD, Egleton RD, Davis TP (2002) Pluronic p85 block copolymer enhances opioid peptide analgesia. J Pharmacol Exp Ther 303:760.
165. Wolka AM, Huber JD, Davis TP (2003) Pain and the blood-brain barrier: Obstacles to drug delivery. Adv Drug Deliv Rev 55:987.
166. Woodle MC, Lasic DD (1992) Sterically stabilized liposomes. Biochem Biophys Acta 1113:171.
167. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y, Yan Z, Li Y (2005) In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 288:361.
168. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K (2001) Longcirculating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. J Control Release 77:27.
169. Yoshida J, Mizuno M (2003) Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J Neurooncol 65:261.
170. Yoshida J, Mizuno M, Fujii M, Kajita Y, Nakahara N, Hatano M, Saito R, Nobayashi M, Wakabayashi T (2004) Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther 15:77.
171. Zhang Y, Schlachetzki F, Pardridge WM (2003a) Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 7:11.
172. Zhang YF, Boado RJ, Pardridge WM (2003b) Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 20:1779.
173. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ, Pardridge WM (2004) Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10:3667.
174. Zhu C, Zhang Y, Zhang YF, Yi Li J, Boado RJ, Pardridge WM (2004) Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med 6:906.
175. Zlokovic BV (1997) Can blood-brain barrier play a role in the development of cerebral amyloids and Alzheimer's disease pathology? Neurobiol Dis 4:23.